Familial CLL
Trial overview
Genetic study of B-cell chronic lymphocytic leukaemia and other lymphoproliferative disease.
Inclusion criteria
Patients with CLL will be invited to participate by their clinician and be provided with an information sheet summarising the study.
Contact details
Other trials currently active for Chronic Lymphocytic Leukaemia
Does the Addition of Mitoxantrone Improve Response to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia
CLL Lenalidomide Maintanence 002 - The Continuum Trial
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA FOLLOWING SECOND-LINE THERAPY (The Continuum Trial)
A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukaemia
Primary Outcome Measures:
•Progression-free-survival (PFS)
Secondary Outcome Measures:
•Overall response rate
•Overall survival
•Clinical benefit, safety, tolerability, changes in patient reported outcome measures and pharmacokinetics
A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia
Attenuated dose Rituximab with ChemoTherapy In CLL: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)
A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Study Of The Safety And Efficacy Of Different Lenalidomide (Revlimid®) Dose Regimens In Subjects With Relapsed Or Refractory B-Cell Chronic Lymphocytic Leukemia